News headlines about PRA Health Sciences (NASDAQ:PRAH) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 47.5497251700282 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- $678.55 Million in Sales Expected for PRA Health Sciences (PRAH) This Quarter (americanbankingnews.com)
- ICON (ICLR) versus PRA Health Sciences (PRAH) Head to Head Review (americanbankingnews.com)
- Head to Head Contrast: PRA Health Sciences (PRAH) and Luna Innovations (LUNA) (americanbankingnews.com)
- $0.94 Earnings Per Share Expected for PRA Health Sciences (PRAH) This Quarter (americanbankingnews.com)
- IQVIA Has Fallen 2.9%, but Analysts Are Still on Board (finance.yahoo.com)
PRAH has been the subject of several analyst reports. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 23rd. Mizuho lowered PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target on the stock. in a research report on Wednesday, January 24th. KeyCorp reissued a “buy” rating and set a $100.00 price target on shares of PRA Health Sciences in a research report on Wednesday, January 31st. Credit Suisse Group reissued an “outperform” rating and set a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a research report on Thursday, February 22nd. Finally, Zacks Investment Research lowered PRA Health Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $95.67.
PRA Health Sciences opened at $80.22 on Monday, MarketBeat Ratings reports. The firm has a market cap of $5.14 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 1.24 and a beta of 0.50. PRA Health Sciences has a 1-year low of $69.29 and a 1-year high of $95.90. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 1.29.
PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, April 25th. The medical research company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.01. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. The company had revenue of $701.80 million for the quarter, compared to analyst estimates of $694.73 million. During the same period in the prior year, the firm posted $0.62 EPS. The business’s revenue was up 43.9% compared to the same quarter last year. equities research analysts predict that PRA Health Sciences will post 3.81 EPS for the current year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.